A Phase 1 Mass Balance Study of 14C‐Labeled Talazoparib in Patients With Advanced Solid Tumors

Adult Aged, 80 and over Male Administration, Oral Middle Aged 6. Clean water 3. Good health Feces 03 medical and health sciences 0302 clinical medicine Neoplasms Humans Phthalazines Female Carbon Radioisotopes Aged Half-Life
DOI: 10.1002/jcph.1415 Publication Date: 2019-04-09T16:54:43Z
ABSTRACT
Abstract This paper describes the pharmacokinetics (PK), mass balance, metabolic profiling, and safety of talazoparib after a single oral dose 14 C‐talazoparib in 6 patients with advanced solid tumors. Patients were aged ≥18 years, histologically confirmed tumor at screening. A 1‐mg solution supplemented 100 µCi C‐labeled was administered. Blood, urine, feces samples collected various time points analyzed for C radioactivity. Metabolic profiling identification also carried out. Mean recovery radioactivity 68.7% urine 19.7% feces. Talazoparib minimally metabolized. Renal excretion unchanged major route elimination, mean 54.6% administered dose, whereas fecal limited, 13.6% dose. No metabolites identified plasma, no that individually represented more than 10% recovered or The concentration‐time profiles talazoparib, total whole blood similar, median peak concentrations 30 minutes half‐life 89.8, 96.2, 77.6 hours, respectively. metabolized, renal elimination.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (8)
CITATIONS (17)